Form POS AM Oruka Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500, Nasdaq futures rise on tech boost
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
Stifel Reiterates Buy Rating on Oruka Therapeutics (ORKA)
March 7, 2025 7:41 AM ESTStifel analyst Alex Thompson reiterated a Buy rating and $49.00 price target on Oruka Therapeutics (NASDAQ: ORKA)
The analyst comments "We are reiterating our Buy rating following ORKA's 4Q24 update. We think ORKA is well-positioned to drive continued innovation in the psoriasis market (and beyond)... More
